1265 related articles for article (PubMed ID: 28858473)
1. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
2. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
4. Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages.
Ngambenjawong C; Cieslewicz M; Schellinger JG; Pun SH
J Control Release; 2016 Feb; 224():103-111. PubMed ID: 26772876
[TBL] [Abstract][Full Text] [Related]
5. M2pep-Modified Cyclodextrin-siRNA Nanoparticles Modulate the Immunosuppressive Tumor Microenvironment for Prostate Cancer Therapy.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Mol Pharm; 2023 Nov; 20(11):5921-5936. PubMed ID: 37874541
[TBL] [Abstract][Full Text] [Related]
6. Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer.
Sun Y; Cronin MF; Mendonça MCP; Guo J; O'Driscoll CM
Eur J Pharm Sci; 2023 Jun; 185():106427. PubMed ID: 36948408
[TBL] [Abstract][Full Text] [Related]
7. Remodeling tumor immune microenvironment via targeted blockade of PI3K-γ and CSF-1/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy.
Li M; Li M; Yang Y; Liu Y; Xie H; Yu Q; Tian L; Tang X; Ren K; Li J; Zhang Z; He Q
J Control Release; 2020 May; 321():23-35. PubMed ID: 32035193
[TBL] [Abstract][Full Text] [Related]
8. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
9. Surface Modification of Polymeric Nanoparticles with M2pep Peptide for Drug Delivery to Tumor-Associated Macrophages.
Pang L; Pei Y; Uzunalli G; Hyun H; Lyle LT; Yeo Y
Pharm Res; 2019 Mar; 36(4):65. PubMed ID: 30859335
[TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing.
Zins K; Abraham D
Methods Mol Biol; 2020; 2115():289-325. PubMed ID: 32006408
[TBL] [Abstract][Full Text] [Related]
11. In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α-Mannosyl-Functionalized Cationic Nanohydrogel Particles.
Kaps L; Leber N; Klefenz A; Choteschovsky N; Zentel R; Nuhn L; Schuppan D
Cells; 2020 Aug; 9(8):. PubMed ID: 32824208
[TBL] [Abstract][Full Text] [Related]
12. Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy.
Wang Y; Luan Z; Zhao C; Bai C; Yang K
Eur J Pharm Sci; 2020 Jan; 142():105136. PubMed ID: 31704343
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.
Cieslewicz M; Tang J; Yu JL; Cao H; Zavaljevski M; Motoyama K; Lieber A; Raines EW; Pun SH
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):15919-24. PubMed ID: 24046373
[TBL] [Abstract][Full Text] [Related]
14. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
[TBL] [Abstract][Full Text] [Related]
15. Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer.
Lu CS; Shiau AL; Su BH; Hsu TS; Wang CT; Su YC; Tsai MS; Feng YH; Tseng YL; Yen YT; Wu CL; Shieh GS
J Hematol Oncol; 2020 Jun; 13(1):62. PubMed ID: 32487125
[TBL] [Abstract][Full Text] [Related]
16. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
Yang M; Li J; Gu P; Fan X
Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
[TBL] [Abstract][Full Text] [Related]
17. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy.
Liu L; Yi H; He H; Pan H; Cai L; Ma Y
Biomaterials; 2017 Jul; 134():166-179. PubMed ID: 28463694
[TBL] [Abstract][Full Text] [Related]
18. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
19. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
[TBL] [Abstract][Full Text] [Related]
20. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
